Adenovirus Production

Oncolytics

Systemic delivery of proprietary ‘stealth’ viruses
Active and passive targeting to tumours
Versatile delivery technology – for any virus

Hybrid Immune

Antibody resistant vectors
Targeted infection of antigen-presenting cells
Co-delivery of adjuvants and TLR ligands

Hybrid Systems Contract Research

Mammalian tissue culture
Cytotoxicity assays
Viral vectors – off the shelf and custom synthesis